Skip to main content
SpringerLink
Log in

Rheumatologic Manifestations of CF

  • Chapter
  • First Online:
Cystic Fibrosis

Part of the book series: Respiratory Medicine ((RM))

  • 1391 Accesses

Abstract

While the pulmonary manifestations of cystic fibrosis (CF) most obviously contribute to the morbidity and mortality of the disease, many patients with CF suffer from bone and joint manifestations as well. A subset of patients with CF experience severe intermittent joint pain from an episodic arthropathy, progressive joint pain from hypertrophic pulmonary osteoarthropathy, or joint pain due to extensive use of fluoroquinolone antibiotics. Others may experience an idiopathic vasculitic rash. The majority of patients with CF will experience decreased bone mineral density as they age, in some cases leading to pathologic fractures. Understanding and treating these conditions is important to providing optimal care for children and adults with CF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bourke S, Rooney M, Fitzgerald M, Bresnihan B. Episodic arthropathy in adult cystic fibrosis. Q J Med. 1987;64:651–9.

    CAS  PubMed  Google Scholar 

  2. Dixey J, et al. The arthropathy of cystic fibrosis. Ann Rheum Dis. 1988;47:218–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Fitch G, et al. Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy. J Cyst Fibros. 2016;15:e35–40.

    CAS  PubMed  Google Scholar 

  4. Koch A-K, Brömme S, Wollschläger B, Horneff G, Keyszer G. Musculoskeletal manifestations and rheumatic symptoms in patients with cystic fibrosis (CF) —no observations of CF-specific arthropathy. J Rheumatol. 2008;35:1882–91.

    PubMed  Google Scholar 

  5. Massie RJ, et al. The musculoskeletal complications of cystic fibrosis. J Paediatr Child Health. 1998;34:467–70.

    CAS  PubMed  Google Scholar 

  6. Newman AJ, Ansell BM. Episodic arthritis in children with cystic fibrosis. J Pediatr. 1979;94:594–6.

    CAS  PubMed  Google Scholar 

  7. Pertuiset E, et al. Cystic fibrosis arthritis. A report of five cases. Br J Rheumatol. 1992;31:535–8.

    CAS  PubMed  Google Scholar 

  8. Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med. 1986;79:44–50.

    PubMed  PubMed Central  Google Scholar 

  9. Rush PJ, et al. The musculoskeletal manifestations of cystic fibrosis. Semin Arthritis Rheum. 1986;15:213–25.

    CAS  PubMed  Google Scholar 

  10. Schidlow DV, Goldsmith DP, Palmer J, Huang NN. Arthritis in cystic fibrosis. Arch Dis Child. 1984;59:377–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Wulffraat NM, de Graeff-Meeder ER, Rijkers GT, van der Laag H, Kuis W. Prevalence of circulating immune complexes in patients with cystic fibrosis and arthritis. J Pediatr. 1994;125:374–8.

    CAS  PubMed  Google Scholar 

  12. Summers GD, Webley M. Episodic arthritis in cystic fibrosis: a case report. Br J Rheumatol. 1986;25:393–5.

    CAS  PubMed  Google Scholar 

  13. Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis – the characteristics of long-term survivors of cystic fibrosis. Respir Med. 2009;103:629–35.

    PubMed  Google Scholar 

  14. Jawad A, Pákozdi A, Watson D, Kuitert L. OP0112 cystic fibrosis related arthritis in adults in south East England. Ann Rheum Dis. 2013;71:91.

    Google Scholar 

  15. Horsley A, et al. Gout and hyperuricaemia in adults with cystic fibrosis. J R Soc Med. 2011;104:S36–9.

    PubMed  PubMed Central  Google Scholar 

  16. Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23:320–7.

    PubMed  Google Scholar 

  17. González-Gay MA, García-Porrúa C, Pujol RM, Salvarani C. Erythema nodosum: a clinical approach. Clin Exp Rheumatol. 2001;19:365–8.

    PubMed  Google Scholar 

  18. Merkel PA. Rheumatic disease and cystic fibrosis. Arthritis Rheum. 1999;42:1563–71.

    CAS  PubMed  Google Scholar 

  19. Thornton J, Rangaraj S. Anti-inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis-related arthritis. Cochrane Libr. 2016;1:1465–1858.

    Google Scholar 

  20. Liou TG, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005;171:1053–9.

    PubMed  Google Scholar 

  22. Martínez-Lavín M, Matucci-Cerinic M, Jajic I, Pineda C. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20:1386–7.

    PubMed  Google Scholar 

  23. Bresnihan B. Cystic fibrosis, chronic bacterial infection, and rheumatic disease. Rheumatology. 1988;27:339–41.

    CAS  Google Scholar 

  24. Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38:458–66.

    PubMed  Google Scholar 

  25. Cohen AM, et al. Evaluation of pulmonary hypertrophic osteoarthropathy in cystic fibrosis: a comprehensive study. Am J Dis Child. 1986;140:74–7.

    CAS  PubMed  Google Scholar 

  26. Athreya BH, Borns P, Rosenlund ML. Cystic fibrosis and hypertrophic osteoarthropathy in children: report of three cases. Am J Dis Child. 1975;129:634–7.

    CAS  PubMed  Google Scholar 

  27. Braude S, Kennedy H, Hodson M, Batten J. Hypertrophic osteoarthropathy in cystic fibrosis. Br Med J Clin Res Ed. 1984;288:822–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Grossman H, Denning CR, Baker DH. Hyperthrophic osteoarthropathy in cystic fibrosis. Am J Dis Child. 1964;1960(107):1–6.

    Google Scholar 

  29. Turner MA, Baildam E, Patel L, David TJ. Joint disorders in cystic fibrosis. J R Soc Med. 1997;90(Suppl 31):13–20.

    PubMed  PubMed Central  Google Scholar 

  30. Matthay MA, Matthay RA, Mills DM, Lakshminarayan S, Cotton E. Hypertrophic osteoarthropathy in adults with cystic fibrosis. Thorax. 1976;31:572–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Nathanson I, Riddlesberger MM. Pulmonary hypertrophic osteoarthropathy in cystic fibrosis. Radiology. 1980;135:649–51.

    CAS  PubMed  Google Scholar 

  32. Cengiz A, Eren MŞ, Polatli M, Yürekli Y. Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with lung adenocarcinoma. Indian J Nucl Med. 2015;30:251–3.

    PubMed  PubMed Central  Google Scholar 

  33. Letts M, Pang E, Simons J. Prostaglandin-induced neonatal periostitis. J Pediatr Orthop. 1994;14:809–13.

    CAS  PubMed  Google Scholar 

  34. Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987;330:1434–5.

    Google Scholar 

  35. Martinez-Lavin M. Exploring the cause of the most ancient clinical sign of medicine: finger clubbing. Semin Arthritis Rheum. 2007;36:380–5.

    PubMed  Google Scholar 

  36. Silveira LH, et al. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol. 2000;18:57–62.

    CAS  PubMed  Google Scholar 

  37. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203:721–8.

    CAS  PubMed  Google Scholar 

  38. Nguyen S, Hojjati M. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clin Rheumatol. 2011;30:7–13.

    PubMed  Google Scholar 

  39. Flavell G. Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy. Lancet. 1956;270:260–2.

    CAS  PubMed  Google Scholar 

  40. Blackwell N, Bangham L, Hughes M, Melzack D, Trotman I. Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac. Thorax. 1993;48:401.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Kozak KR, Milne GL, Morrow JD, Cuiffo BP. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. Nat Clin Pract Rheumatol. 2006;2:452–6; quiz following 456.

    PubMed  Google Scholar 

  42. Leung FW, Williams AJ, Fan P. Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma. West J Med. 1985;142:345–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Angel-Moreno Maroto A, Martínez-Quintana E, Suárez-Castellano L, Pérez-Arellano J-L. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology. 2005;44:1326–7.

    CAS  PubMed  Google Scholar 

  44. Johnson SA, Spiller PA, Faull CM. Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide. Thorax. 1997;52:298–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. López-Enriquez E, Morales AR, Robert F. Effect of atropine sulfate in pulmonary hypertrophic osteoarthropathy. Arthritis Rheum. 1980;23:822–4.

    PubMed  Google Scholar 

  46. Reardon G, Collins AJ, Bacon PA. The effect of adrenergic blockade in hypertrophic pulmonary osteoarthropathy (HPOA). Postgrad Med J. 1976;52:170–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Diner WC, Rock L. Hypertrophie osteoarthropathy: relief of symptoms by vagotomy in a patient with pulmonary metastases from a lympho-epithelioma of the nasopharynx. JAMA. 1962;181:555–7.

    CAS  PubMed  Google Scholar 

  48. Ooi A, Saad RA, Moorjani N, Amer KM. Effective symptomatic relief of hypertrophic pulmonary osteoarthropathy by video-assisted thoracic surgery truncal vagotomy. Ann Thorac Surg. 2007;83:684–5.

    PubMed  Google Scholar 

  49. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol. 2004;23:330–2.

    PubMed  Google Scholar 

  50. Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest. 2002;121:1363–4.

    PubMed  Google Scholar 

  51. Jayakar BA, Abelson AG, Yao Q. Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. Semin Arthritis Rheum. 2011;41:291–6.

    PubMed  Google Scholar 

  52. King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer. 2008;9:179–82.

    PubMed  Google Scholar 

  53. Mauricio O, et al. Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates. J Thorac Oncol. 2009;4:260–2.

    PubMed  Google Scholar 

  54. Suzuma T, et al. Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anti-Cancer Drugs. 2001;12:731–4.

    CAS  PubMed  Google Scholar 

  55. Molyneux ID, Moon T, Webb AK, Morice AH. Treatment of cystic fibrosis associated cutaneous vasculitis with chloroquine. J Cyst Fibros. 2010;9:439–41.

    CAS  PubMed  Google Scholar 

  56. Soter NA, Mihm MC, Colten HR. Cutaneous necrotizing venulitis in patients with cystic fibrosis. J Pediatr. 1979;95:190–1.

    Google Scholar 

  57. Wujanto L, Ross C. Recurrent vasculitis in cystic fibrosis. BMJ Case Rep. 2010;2010

    Google Scholar 

  58. Garty BZ, Scanlin T, Goldsmith DP, Grunstein M. Cutaneous manifestations of cystic fibrosis: possible role of cryoglobulins. Br J Dermatol. 1989;121:655–8.

    CAS  PubMed  Google Scholar 

  59. Hodson ME. Vasculitis and arthropathy in cystic fibrosis. J R Soc Med. 1992;85:38–40.

    PubMed  PubMed Central  Google Scholar 

  60. John EG, Medenis R, Rao S. Cutaneous necrotizing venulitis in patients with cystic fibrosis [letter]. J Pediatr. 1980;97:505.

    CAS  PubMed  Google Scholar 

  61. Nielsen HE, Lundh S, Jacobsen SV, Høiby N. Hypergammagolbulinemic purpura in cystic fibrosis. Acta Paediatr. 1978;67:443–7.

    CAS  Google Scholar 

  62. Finnegan MJ, et al. Vasculitis complicating cystic fibrosis. Q J Med. 1989;72:609–21.

    CAS  PubMed  Google Scholar 

  63. Hilton AM, et al. Cutaneous vasculitis and immune complexes in severe bronchiectasis. Thorax. 1984;39:185–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Schultz H, Weiss JP. The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin Chim Acta. 2007;384:12–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Sedivá A, et al. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J Autoimmun. 1998;11:185–90.

    PubMed  Google Scholar 

  66. Iovine NM, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci U S A. 1997;94:10973–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol. 1998;64:14–8.

    CAS  PubMed  Google Scholar 

  68. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol. 1998;10:45–9.

    CAS  PubMed  Google Scholar 

  69. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol. 1995;99:49–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Van der Schaft DW, Toebes EA, Haseman JR, Mayo KH, Griffioen AW. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood. 2000;96:176–81.

    PubMed  Google Scholar 

  71. Arditi M, et al. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. Infect Immun. 1994;62:3930–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Mahadeva R, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol. 1999;117:561–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Zhao MH, et al. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM. 1996;89:259–65.

    CAS  PubMed  Google Scholar 

  74. Döring G, Albus A, Høiby N. Immunologic aspects of cystic fibrosis. Chest. 1988;94:109S–14S.

    PubMed  Google Scholar 

  75. Mathieu JP, Stack BH, Dick WC, Buchanan WW. Pulmonary infection and rheumatoid arthritis. Br J Dis Chest. 1978;72:57–61.

    CAS  PubMed  Google Scholar 

  76. Finder KA, McCollough ML, Dixon SL, Majka AJ, Jaremko W. Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol. 1990;23:669–76.

    CAS  PubMed  Google Scholar 

  77. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2007;29:522–6.

    CAS  PubMed  Google Scholar 

  78. Lindberg U, Carlsson M, Löfdahl C-G, Segelmark M. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study. Clin Dev Immunol. 2012;2012:370107.

    PubMed  PubMed Central  Google Scholar 

  79. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985;28:581–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Lode H, et al. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother. 1990;26(Suppl B):41–9.

    CAS  PubMed  Google Scholar 

  81. Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990;19:434–61.

    CAS  PubMed  Google Scholar 

  82. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985;28:716–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother. 1995;35:317–26.

    CAS  PubMed  Google Scholar 

  84. Lee LJ, et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy. 1998;18:35–41.

    CAS  PubMed  Google Scholar 

  85. Wise R, Baldwin DR, Andrews JM, Honeybourne D. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother. 1991;28(Suppl C):65–71.

    CAS  PubMed  Google Scholar 

  86. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol. 1990;27:162–70.

    CAS  PubMed  Google Scholar 

  87. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesia FA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51:177–87.

    CAS  PubMed  Google Scholar 

  88. Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol. 1988;11:110–9.

    CAS  PubMed  Google Scholar 

  89. Shakibaei M, et al. Comparative evaluation of ultrastructural changes in articular cartilage of ofloxacin-treated and magnesium-deficient immature rats. Toxicol Pathol. 1996;24:580–7.

    CAS  PubMed  Google Scholar 

  90. Stahlmann R, et al. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol. 1990;64:193–204.

    CAS  PubMed  Google Scholar 

  91. Menschik M, et al. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro. Antimicrob Agents Chemother. 1997;41:2562–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother. 1990;26:25–9.

    PubMed  Google Scholar 

  93. Chalumeau M, et al. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France. Pediatrics. 2003;111:e714–9.

    PubMed  Google Scholar 

  94. Church DA, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J. 1997;16:97.

    CAS  PubMed  Google Scholar 

  95. Raeburn JA, et al. Ciprofloxacin therapy in cystic fibrosis. J Antimicrob Chemother. 1987;20:295–6.

    CAS  PubMed  Google Scholar 

  96. Richard DA, et al. Oral ciprofloxacin vs intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging Cystic Fibrosis Study Group. Pediatr Infect Dis J. 1997;16:572–8.

    CAS  PubMed  Google Scholar 

  97. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis. 1990;13:153–5.

    CAS  PubMed  Google Scholar 

  98. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J. 1997;16:106–11; discussion 123–126.

    CAS  PubMed  Google Scholar 

  99. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96:874–80.

    PubMed  PubMed Central  Google Scholar 

  100. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients--review. Infection. 1993;21:413–21.

    CAS  PubMed  Google Scholar 

  101. Chyský V, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection. 1991;19:289–96.

    PubMed  Google Scholar 

  102. Cruciani M, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study. Infection. 1989;17:65–9.

    CAS  PubMed  Google Scholar 

  103. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection. 1987;15:165–8.

    CAS  PubMed  Google Scholar 

  104. Redmond A, et al. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. J Int Med Res. 1998;26:304–12.

    CAS  PubMed  Google Scholar 

  105. Aricò M, et al. Long-term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones. Pediatr Infect Dis J. 1995;14:713–4.

    PubMed  Google Scholar 

  106. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21:525–9.

    PubMed  Google Scholar 

  107. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. ET J. 1992;11:1047–9.

    CAS  Google Scholar 

  108. Adam D. Use of quinolones in pediatric patients. Rev Infect Dis. 1989;11(Suppl 5):S1113–6.

    PubMed  Google Scholar 

  109. Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2016;138:e20162706.

    PubMed  Google Scholar 

  110. Schaad UB, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995;14:1–9.

    CAS  PubMed  Google Scholar 

  111. Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti-Infect Ther. 2006;4:853–60.

    CAS  PubMed  Google Scholar 

  112. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003;22:1128.

    PubMed  Google Scholar 

  113. Bhudhikanok GS, et al. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics. 1996;97:103–11.

    CAS  PubMed  Google Scholar 

  114. Bhudhikanok GS, et al. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr. 1998;133:18–27.

    CAS  PubMed  Google Scholar 

  115. Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr. 1996;128:28–34.

    CAS  PubMed  Google Scholar 

  116. Shane E, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996;101:262–9.

    CAS  PubMed  Google Scholar 

  117. Gibbens DT, et al. Osteoporosis in cystic fibrosis. J Pediatr. 1988;113:295–300.

    CAS  PubMed  Google Scholar 

  118. Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax. 1993;48:589–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  119. Rochat T, Slosman DO, Pichard C, Belli DC. Body composition analysis by dual-energy X-ray absorptiometry in adults with cystic fibrosis. Chest. 1994;106:800–5.

    CAS  PubMed  Google Scholar 

  120. Bachrach LK, Loutit CW, Moss RB. Osteopenia in adults with cystic fibrosis. Am J Med. 1994;96:27–34.

    CAS  PubMed  Google Scholar 

  121. Conway S, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax. 2000;55:798–804.

    CAS  PubMed  PubMed Central  Google Scholar 

  122. Mischler EH, Chesney PJ, Chesney RW, Mazess RB. Demineralization in cystic fibrosis: detected by direct photon absorptiometry. Am J Dis Child. 1979;133:632–5.

    CAS  PubMed  Google Scholar 

  123. Hahn TJ, Squires AE, Halstead LR, Strominger DB. Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J Pediatr. 1979;94:38–42.

    CAS  PubMed  Google Scholar 

  124. Elkin SL, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int. 2001;12:366–72.

    CAS  PubMed  Google Scholar 

  125. Henderson RC, Madsen CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. Pediatr Pulmonol. 1999;27:80–4.

    CAS  PubMed  Google Scholar 

  126. Haworth CS, et al. Low bone mineral density in adults with cystic fibrosis. Thorax. 1999;54:961–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  127. Tschopp O, et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant. 2002;2:167–72.

    PubMed  Google Scholar 

  128. Shaw N, Bedford C, Heaf D, Carty H, Dutton J. Osteopenia in adults with cystic fibrosis. Am J Med. 1995;99:690–2.

    CAS  PubMed  Google Scholar 

  129. Baroncelli GI, et al. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res. 1997;41:397–403.

    CAS  PubMed  Google Scholar 

  130. Donovan DS, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med. 1998;157:1892–9.

    PubMed  Google Scholar 

  131. King SJ, et al. Reduced bone density in cystic fibrosis: ΔF508 mutation is an independent risk factor. Eur Respir J. 2005;25:54–61.

    CAS  PubMed  Google Scholar 

  132. Donadio MVF, et al. Bone mineral density, pulmonary function, chronological age, and age at diagnosis in children and adolescents with cystic fibrosis. J Pediatr. 2013;89:151–7.

    Google Scholar 

  133. Parasa RB, Maffulli N. Musculoskeletal involvement in cystic fibrosis. Bull Hosp Jt Dis N Y N. 1999;58:37–44.

    CAS  Google Scholar 

  134. Aris RM, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med. 1998;128:186–93.

    CAS  PubMed  Google Scholar 

  135. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2010;86:1–7.

    CAS  PubMed  Google Scholar 

  136. Laursen EM, Mølgaard C, Michaelsen KF, Koch C, Müller J. Bone mineral status in 134 patients with cystic fibrosis. Arch Dis Child. 1999;81:235–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  137. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–36.

    PubMed  Google Scholar 

  138. Henderson RC, Specter BB. Kyphosis and fractures in children and young adults with cystic fibrosis. J Pediatr. 1994;125:208–12.

    CAS  PubMed  Google Scholar 

  139. Sirmali M, et al. A comprehensive analysis of traumatic rib fractures: morbidity, mortality and management. Eur J Cardiothorac Surg. 2003;24:133–8.

    PubMed  Google Scholar 

  140. Lorbergs AL, et al. Severity of kyphosis and decline in lung function: the Framingham study. J Gerontol A Biol Sci Med Sci. 2017;72:689–94.

    PubMed  Google Scholar 

  141. Culham EG, Jimenez HA, King CE. Thoracic kyphosis, rib mobility, and lung volumes in normal women and women with osteoporosis. Spine. 1994;19:1250–5.

    CAS  PubMed  Google Scholar 

  142. Ravilly S, Robinson W, Suresh S, Wohl ME, Berde CB. Chronic pain in cystic fibrosis. Pediatrics. 1996;98:741–7.

    CAS  PubMed  Google Scholar 

  143. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res. 1993;8:567–73.

    CAS  PubMed  Google Scholar 

  144. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19:595–606.

    CAS  PubMed  Google Scholar 

  145. Salamoni F, et al. Bone mineral content in cystic fibrosis patients: correlation with fat-free mass. Arch Dis Child. 1996;74:314–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  146. Hardin DS, Arumugam R, Seilheimer DK, LeBlanc A, Ellis KJ. Normal bone mineral density in cystic fibrosis. Arch Dis Child. 2001;84:363–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  147. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest. 1996;109:1176–83.

    CAS  PubMed  Google Scholar 

  148. Reid IR, Grey AB. Corticosteroid osteoporosis. Baillieres Clin Rheumatol. 1993;7:573–87.

    CAS  PubMed  Google Scholar 

  149. Sambrook P, Lane NE. Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol. 2001;15:401–13.

    CAS  PubMed  Google Scholar 

  150. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246.

    PubMed  Google Scholar 

  151. Johannesson M, Gottlieb C, Hjelte L. Delayed puberty in girls with cystic fibrosis despite good clinical status. Pediatrics. 1997;99:29–34.

    CAS  PubMed  Google Scholar 

  152. Bailey DA, Mckay HA, Mirwald RL, Crocker PRE, Faulkner RA. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the University of Saskatchewan Bone Mineral Accrual Study. J Bone Miner Res. 1999;14:1672–9.

    CAS  PubMed  Google Scholar 

  153. Alswat K, Gender A. Disparities in osteoporosis. J Clin Med Res. 2017;9:382–7.

    PubMed  PubMed Central  Google Scholar 

  154. Cawthon P, Gender M. Differences in osteoporosis and fractures. Clin Orthop. 2011;469:1900–5.

    PubMed  Google Scholar 

  155. Baim S, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11:6–21.

    PubMed  Google Scholar 

  156. Smith J, Shoukri K. Diagnosis of osteoporosis. Clin Cornerstone. 2000;2:22–30.

    CAS  PubMed  Google Scholar 

  157. Brown SA, et al. Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis. Osteoporos Int. 2003;14:442–9.

    CAS  PubMed  Google Scholar 

  158. Haworth CS, Jones AM, Adams JE, Selby PL, Webb AK. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros. 2004;3:233–6.

    CAS  PubMed  Google Scholar 

  159. Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest. 2008;118:3841–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  160. Aris RM, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med. 2004;169:77–82.

    PubMed  Google Scholar 

  161. Aris RM, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000;162:941–6.

    CAS  PubMed  Google Scholar 

  162. Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax. 2004;59:699–703.

    CAS  PubMed  PubMed Central  Google Scholar 

  163. Haworth CS, et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax. 2001;56:314–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  164. Haworth CS, et al. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet. 1998;352:1753–4.

    CAS  PubMed  Google Scholar 

  165. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Libr. 2014;3:1465–1858.

    Google Scholar 

  166. Bachrach LK, Ward LM. Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94:400–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint Louis Children’s Hospital, Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA

    Amanda Reis & Andrew J. White

Authors
  1. Amanda Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. White .

Editor information

Editors and Affiliations

  1. The University of North Carolina at Chapel Hill, Department of Pediatrics, UNC Children’s Hospital, Chapel Hill, NC, USA

    Stephanie Duggins Davis

  2. Department of Pediatrics, University of Washington School of Medicine, Division of Pulmonary and Sleep Medicine, Seattle Children’s Hospital, Seattle, WA, USA

    Margaret Rosenfeld

  3. Department of Pediatrics, Indiana University School of Medicine, Division of Pediatric Pulmonology, Allergy and Sleep Medicine, Riley Hospital for Children at IU Health, Indianapolis, IN, USA

    James Chmiel

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reis, A., White, A.J. (2020). Rheumatologic Manifestations of CF. In: Davis, S., Rosenfeld, M., Chmiel, J. (eds) Cystic Fibrosis. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-42382-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42382-7_18

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-42381-0

  • Online ISBN: 978-3-030-42382-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation